Corcept Therapeutics Trading Volume Surges to $464 Million Ranking 194th Despite Stock Price Decline

On June 2, 2025, Corcept Therapeutics (CORT) saw a significant surge in trading volume, reaching $464 million, marking a 396.59% increase from the previous day. This placed Corcept among the top 194 most actively traded stocks for the day. However, the stock price experienced a decline of 7.58%.

Corcept Therapeutics has recently announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for Korlym. The FDA has requested additional clinical data to support the safety and efficacy of the drug. This news has led to a decline in the company's stock price, as investors are concerned about the potential delay in the approval process.

Despite the setback, Corcept Therapeutics remains optimistic about the future of Korlym. The company has stated that it is committed to working with the FDA to address their concerns and provide the necessary data to support the approval of the drug. Corcept Therapeutics is also exploring other potential indications for Korlym, which could expand the drug's market potential.

In addition to the news about Korlym, Corcept Therapeutics has also announced that it has entered into a collaboration agreement with a leading biopharmaceutical company to develop a new drug for the treatment of a rare disease. This collaboration is expected to bring in additional revenue for Corcept Therapeutics and further diversify its product portfolio.

Overall, while the recent news about Korlym has led to a decline in Corcept Therapeutics' stock price, the company's long-term prospects remain promising. With a strong pipeline of drugs in development and a commitment to innovation, Corcept Therapeutics is well-positioned to continue growing and delivering value to its shareholders.